PPIDT00444
Drug Information
| Name | Brexucabtagene autoleucel |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15699 |
| Type | biotech |
| Indication | Brexucabtagene autoleucel is a modified autologous chimeric antigen receptor (CAR) T cell immunotherapy indicated for the treatment of relapsed or refractory mantle cell lymphoma (MCL) in adult patients.[L15148] It is additionally indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).[L15148] Brexucabtagene autoleucel has been granted accelerated approval based on results from a single-arm, open-label, multicentre clinical trial; continued approval may be contingent on confirmatory trials.[L15148] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Suspension | Intravenous |
1000000 1/68mL
|
| Suspension | Intravenous |
100000000 cells / bag
|
| Suspension | Intravenous |
120000000 cells
|
| Suspension | Intravenous |
2000000 1/68mL
|
| Suspension | Intravenous |
200000000 cells / bag
|